Detalhe da pesquisa
1.
Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials.
Ann Hepatol
; 15(3): 333-49, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27049487
2.
Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND-C3, a Phase 2b study.
Liver Int
; 35(2): 417-21, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25263751
3.
Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.
Int J Neuropsychopharmacol
; 13(7): 917-32, 2010 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-20175941
4.
Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study.
Eur J Gastroenterol Hepatol
; 28(8): 923-6, 2016 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-27140229
5.
Long-term Safety and Efficacy of Tapentadol Extended Release Following up to 2 Years of Treatment in Patients With Moderate to Severe, Chronic Pain: Results of an Open-label Extension Trial.
Clin Ther
; 37(11): 2420-38, 2015 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26428249
6.
Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study.
Expert Opin Pharmacother
; 11(11): 1787-804, 2010 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-20578811